In another disappointment for investors, FDA slaps down Biohaven’s revised version of an old ALS drug

In another disappointment for investors, FDA slaps down Biohaven’s revised version of an old ALS drug

Source: 
Endpoints
snippet: 

Biohaven is at risk of making a habit of disappointing its investors.

Late Friday the biotech $BHVN reported that the FDA had rejected its application for riluzole, an old drug that they had made over into a sublingual formulation that dissolves under the tongue.